Radioimmunotherapy of brain tumor

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Despite years of intensive research, the prognosis of high-grade gliomas (HGG) remains poor, as these tumors are highly resistant to currently available therapies. Therefore, there is a need for the development of new therapeutic strategies, such as the use of monoclonal antibodies (MoAbs) in association with radioisotopes, in order to achieve better responses and prognosis. This article describes our experience in radioimmunotherapy (RIT) with MoAbs and tumor pretargeting with the avidin-biotin system, either in systemic or locoregional administrations. This therapy offers the exciting prospect of increasing the specificity of tumor cell irradiation with radioisotopes. We suggest that RIT, both systemic and locoregional, should be used as part of a combined modality approach: in combination with surgery, radiotherapy and chemotherapy.

Original languageEnglish
Pages (from-to)518-522
Number of pages5
JournalNeurological Research
Volume28
Issue number5
DOIs
Publication statusPublished - Jul 2006

Fingerprint

Radioimmunotherapy
Brain Neoplasms
Radioisotopes
Monoclonal Antibodies
Neoplasms
Avidin
Biotin
Glioma
Radiotherapy
Therapeutics
Drug Therapy
Research

Keywords

  • Antibodies
  • Glioblastoma
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Radioimmunotherapy of brain tumor. / Paganelli, Giovanni; Bartolomei, Mirco; Grana, Chiara; Ferrari, Mahila; Rocca, Paola; Chinol, Marco.

In: Neurological Research, Vol. 28, No. 5, 07.2006, p. 518-522.

Research output: Contribution to journalArticle

Paganelli, Giovanni ; Bartolomei, Mirco ; Grana, Chiara ; Ferrari, Mahila ; Rocca, Paola ; Chinol, Marco. / Radioimmunotherapy of brain tumor. In: Neurological Research. 2006 ; Vol. 28, No. 5. pp. 518-522.
@article{f14a71ea24f94375a7c7558f59128bb2,
title = "Radioimmunotherapy of brain tumor",
abstract = "Despite years of intensive research, the prognosis of high-grade gliomas (HGG) remains poor, as these tumors are highly resistant to currently available therapies. Therefore, there is a need for the development of new therapeutic strategies, such as the use of monoclonal antibodies (MoAbs) in association with radioisotopes, in order to achieve better responses and prognosis. This article describes our experience in radioimmunotherapy (RIT) with MoAbs and tumor pretargeting with the avidin-biotin system, either in systemic or locoregional administrations. This therapy offers the exciting prospect of increasing the specificity of tumor cell irradiation with radioisotopes. We suggest that RIT, both systemic and locoregional, should be used as part of a combined modality approach: in combination with surgery, radiotherapy and chemotherapy.",
keywords = "Antibodies, Glioblastoma, Radioimmunotherapy",
author = "Giovanni Paganelli and Mirco Bartolomei and Chiara Grana and Mahila Ferrari and Paola Rocca and Marco Chinol",
year = "2006",
month = "7",
doi = "10.1179/016164106X116782",
language = "English",
volume = "28",
pages = "518--522",
journal = "Neurological Research",
issn = "0161-6412",
publisher = "Maney Publishing",
number = "5",

}

TY - JOUR

T1 - Radioimmunotherapy of brain tumor

AU - Paganelli, Giovanni

AU - Bartolomei, Mirco

AU - Grana, Chiara

AU - Ferrari, Mahila

AU - Rocca, Paola

AU - Chinol, Marco

PY - 2006/7

Y1 - 2006/7

N2 - Despite years of intensive research, the prognosis of high-grade gliomas (HGG) remains poor, as these tumors are highly resistant to currently available therapies. Therefore, there is a need for the development of new therapeutic strategies, such as the use of monoclonal antibodies (MoAbs) in association with radioisotopes, in order to achieve better responses and prognosis. This article describes our experience in radioimmunotherapy (RIT) with MoAbs and tumor pretargeting with the avidin-biotin system, either in systemic or locoregional administrations. This therapy offers the exciting prospect of increasing the specificity of tumor cell irradiation with radioisotopes. We suggest that RIT, both systemic and locoregional, should be used as part of a combined modality approach: in combination with surgery, radiotherapy and chemotherapy.

AB - Despite years of intensive research, the prognosis of high-grade gliomas (HGG) remains poor, as these tumors are highly resistant to currently available therapies. Therefore, there is a need for the development of new therapeutic strategies, such as the use of monoclonal antibodies (MoAbs) in association with radioisotopes, in order to achieve better responses and prognosis. This article describes our experience in radioimmunotherapy (RIT) with MoAbs and tumor pretargeting with the avidin-biotin system, either in systemic or locoregional administrations. This therapy offers the exciting prospect of increasing the specificity of tumor cell irradiation with radioisotopes. We suggest that RIT, both systemic and locoregional, should be used as part of a combined modality approach: in combination with surgery, radiotherapy and chemotherapy.

KW - Antibodies

KW - Glioblastoma

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=33746528638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746528638&partnerID=8YFLogxK

U2 - 10.1179/016164106X116782

DO - 10.1179/016164106X116782

M3 - Article

C2 - 16808882

AN - SCOPUS:33746528638

VL - 28

SP - 518

EP - 522

JO - Neurological Research

JF - Neurological Research

SN - 0161-6412

IS - 5

ER -